ChartMill · Aug 21, 2026
Novartis (NYSE:NVS): A Dividend Quality Play for Income Investors
Novartis (NVS) stands out in Best Dividend screen: 7/10 dividend rating, 2.99% yield, strong profitability. A solid dividend pick to watch.
NV
NYSE · NVS
Novartis AG
Healthcare · Drug Manufacturers - General
$153.81
Down-$0.84 (-0.54%)
Updated Aug 31, 2026, 5:35 AM
SID Score
6.7/10
Composite research score
Smart Money
58/100
Neutral
- Market cap
- 258.98B
- P/E ratio
- 18.18
- Dividend yield
- 2.60%
- 52-week range
- $121.57 – $170.46
- Volume
- 1.17M
- Avg. volume
- 1.65M
Price performance
NVS price history
1M range · 20 trading sessions · Daily adjusted prices
NVS closed at $153.81 after 20 trading sessions, up 0.09% for the selected period.
- Last close
- $153.81
- Period change
- +0.09%
- Period low
- $150.88
- Period high
- $160.31
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 28, 2026 | $154.51 | $154.565 | $152.77 | $153.81 | 1.17M |
| Aug 27, 2026 | $155.925 | $155.93 | $154.43 | $154.65 | 1.22M |
| Aug 26, 2026 | $158.41 | $159.19 | $157.44 | $157.54 | 1.47M |
| Aug 25, 2026 | $158.51 | $160.29 | $157.83 | $159.98 | 998.18K |
| Aug 24, 2026 | $157.12 | $158.46 | $156.77 | $158.02 | 801.26K |
| Aug 21, 2026 | $156.17 | $159.715 | $156.10 | $158.86 | 1.18M |
| Aug 20, 2026 | $159.07 | $159.33 | $155.87 | $156.24 | 1.53M |
| Aug 19, 2026 | $156.29 | $160.81 | $156.17 | $160.31 | 2.4M |
| Aug 18, 2026 | $153.58 | $155.10 | $153.38 | $154.55 | 1.41M |
| Aug 17, 2026 | $151.23 | $152.615 | $150.83 | $151.97 | 1.2M |
| Aug 14, 2026 | $149.39 | $151.46 | $149.09 | $150.88 | 1.6M |
| Aug 13, 2026 | $152.84 | $153.02 | $151.53 | $151.72 | 1.52M |
| Aug 12, 2026 | $152.03 | $153.43 | $151.815 | $152.32 | 2.47M |
| Aug 11, 2026 | $156.47 | $157.34 | $154.51 | $154.61 | 1.07M |
| Aug 10, 2026 | $155.84 | $156.93 | $155.39 | $156.79 | 995.48K |
| Aug 7, 2026 | $156.56 | $156.6802 | $155.38 | $156.33 | 1.31M |
| Aug 6, 2026 | $155.58 | $155.885 | $153.67 | $154.21 | 1.05M |
| Aug 5, 2026 | $155.23 | $155.56 | $153.81 | $154.44 | 1.18M |
| Aug 4, 2026 | $154.89 | $154.89 | $152.99 | $153.27 | 1.71M |
| Aug 3, 2026 | $155.66 | $156.37 | $153.02 | $153.67 | 1.67M |
Latest NVS news
The latest Smart Investors Daily articles mentioning NVS.
Stock researchCompany · Overview
NVS research
Overview
Company profile and research snapshot.
Company profile
Novartis develops and manufactures innovative drugs. Key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States comprising close to one third of total revenue.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Hold
- Average target
- $127.00
- Implied upside
- —
- Analysts
- 12
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 14, 2026 | TD COWEN | Hold | — |
| Jul 13, 2026 | ROTHSCHILD & CO REDBURN | Sell | — |
| Jul 13, 2026 | BERENBERG | Hold | — |
| Jul 9, 2026 | ARGUS RESEARCH CORPORATION | Buy | — |
| Jun 30, 2026 | INTESA SANPAOLO EQUITY RESEARCH | Buy | — |
News briefing
No generated briefing is available yet.
Benzinga · Aug 18, 2026
Enliven’s Lead Drug Could Disrupt The Leukemia Treatment Market, Analyst Says
William Blair initiates Enliven Therapeutics (ELVN) with Outperform, highlighting ELVN-001's strong CML trial data & $8.8B market potential.
Benzinga · Aug 7, 2026
Novartis India Approves Termination Of Distribution Agreement With Dr. Reddy’s Laboratories; Termination Agreement With Dr. Reddy’s Effective September 30, 2026; To Re-Buy Exclusivity And Market Access For Products After DRL Agreement Termination
- Reuters
Benzinga · Aug 6, 2026
MHRA Approves Remibrutinib For Adults With Chronic Spontaneous Urticaria
https://www.gov.uk/government/news/mhra-approves-remibrutinib-for-adults-with-chronic-spontaneous-urticaria
AI research layers
Interpretive context generated from the platform’s current data sources.
Novartis AG Stock Performance
Novartis AG shares closed at $153.81, reflecting a 2.92% decline over the trailing one-month period but maintaining a solid 21.45% gain over the past twelve months, per SID market data. The stock currently trades below its 50-day moving average of $154.80, though it remains firmly above the 200-day moving average of $148.85, suggesting the longer-term uptrend is intact despite near-term weakness. The 14-day relative strength index registers at 45.2, indicating neither overbought nor oversold conditions. Over the trailing three-month window, NVS has posted a modest 2.42% gain. The stock carries a beta of 0.438, according to Massive/Polygon data, underscoring its defensive profile relative to the broader market. Average daily trading volume stands at approximately 1.65 million shares. Novartis holds a market capitalization of approximately $259 billion, positioning it among the largest global pharmaceutical companies by market value.
Novartis AG Valuation Analysis
Novartis AG currently trades at a price-to-earnings ratio of 18.18, per SID market data, a level broadly in line with large-cap healthcare sector peers. The company's price-to-book ratio stands at 5.90, according to SEC filings, reflecting the premium investors assign to Novartis's diversified pharmaceutical portfolio and intellectual property assets. The PEG ratio registers at negative 0.79, a figure that limits its analytical utility as a growth-adjusted valuation metric in this context. Novartis offers a dividend yield of approximately 3.31%, which remains attractive relative to the broader healthcare sector and positions the stock as a notable income-generating holding for dividend-focused portfolios. The combination of a sub-20 P/E multiple with a yield exceeding 3% places Novartis in a valuation range that balances earnings capitalization with shareholder return, consistent with the company's mature pharmaceutical business model and steady cash flow generation profile.
Smart Money Activity for NVS
Novartis AG carries a composite smart money score of 58 out of 100, reflecting a neutral overall signal, per SID market data. Institutional activity is the strongest component, scoring 21.0 out of 25, indicating robust participation from large fund managers and asset allocators in the stock. Insider activity scores 12.5 out of 25, suggesting moderate but unremarkable transaction patterns among company executives and directors, according to SEC Form 4 filings. Dark pool activity registers at 12.0 out of 25, pointing to average levels of off-exchange institutional trading volume. Congressional trading interest scores 12 out of 25, reflecting limited but present activity among disclosed congressional portfolios. The elevated institutional sub-score stands out as the dominant driver of smart money engagement with NVS, consistent with the company's status as a mega-cap pharmaceutical name favored by large-scale institutional allocators. No extreme positioning signals emerge from the composite data, per 13F institutional filings, supporting the neutral classification.
Novartis AG Earnings Outlook
Novartis AG most recently reported quarterly earnings per share of $2.41, surpassing the consensus analyst estimate of $2.16 by $0.25, representing an 11.6% positive surprise, according to company earnings reports. This followed a prior quarter in which EPS of $1.99 missed the $2.07 estimate by $0.08, a negative surprise of approximately 3.9%. Looking ahead, analyst estimates project EPS of $2.10 for the upcoming quarter with results expected on May 1, 2026, followed by $2.13 for the subsequent period with a July 16, 2026 reporting date. The sequential increase in estimates from $2.10 to $2.13 reflects modest anticipated earnings growth over the near term. Novartis's ability to deliver a meaningful beat in its latest quarter following a prior miss demonstrates earnings volatility within a relatively narrow band, consistent with the predictable revenue base typical of diversified pharmaceutical companies.
Wall Street Analyst Ratings for NVS
Wall Street analyst sentiment on Novartis AG reflects a mixed consensus, per SID consensus data. In the most recent round of coverage updates, TD Cowen reiterated a Hold rating on July 14, 2026, while Berenberg similarly maintained its Hold stance on July 13, 2026. Argus Research Corporation upgraded NVS to Buy from Hold on July 9, 2026, representing the most notable positive shift in recent coverage. Intesa Sanpaolo Equity Research maintained a Buy rating on June 30, 2026, adding to the bullish contingent. Conversely, Rothschild & Co Redburn reiterated a Sell rating on July 13, 2026, according to Wall Street analyst reports, marking it as the sole bearish voice among recent updates. The distribution of ratings — two Buy, two Hold, and one Sell across the five most recent actions — illustrates a lack of strong directional consensus among covering analysts. The Argus upgrade from Hold to Buy stands as the only rating change among recent actions, with all other firms maintaining prior positions.
